ESMO Breast 2021 | Promising novel approaches to the treatment of TNBC

Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. Elisa Agostinetto, MD, Istituto Clinico Humanitas, Rozzano, Milan, Italy, discusses the treatment landscape for TNBC, highlighting promising novel therapy approaches including repurposing of approved drugs in new settings, the use of immune checkpoint inhibitors and the potential role of sacituzumab govetican. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.